Osimertinib vs. afatinib as first-line treatment for patients with metastatic non-small cell lung cancer with an EGFR exon 19 deletion or exon 21 L858R mutation
Journal of Thoracic Disease · 2023-11 · 15 (11) · 6115-6125
DOI: 10.21037/jtd-23-686 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Thoracic Disease, 2023-11. Verfasst von Sophia Gilardone und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Hospital of the University of Pennsylvania, Philadelphia, PA, USA. Die Arbeit wurde bisher 10-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
The optimal treatment sequencing for patients with metastatic epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) remains a subject of debate. In the United States, osimertinib is the preferred EGFR tyrosine kinase inhibitor (TKI) in the first-line setting. However, small retrospective studies suggest that alternative EGFR TKI sequencing strategies may produce similar outcomes. This study aimed to compare the outcomes of patients with metastatic NSCLC harboring an EGFR exon 19 deletion or exon 21 L858R mutation treated with osimertinib vs. afatinib as first-line therapy.
Methods
This retrospective, single-institution study examined 86 patients with metastatic EGFR-mutant NSCLC treated with either afatinib (n=15) or osimertinib (n=71) in the first-line setting. The primary outcome was progression-free survival (PFS), and secondary endpoints included time on EGFR TKI, overall survival (OS), and the incidence of adverse events (AEs).
Results
There was no difference in the PFS (median: 27.9 vs. 29.0 months, P=0.75), OS (P=0.18), and the median time on first-line EGFR TKI (23.9 vs. 15.2 months, P=0.10) between the afatinib and osimertinib groups, respectively. The number of AEs was also similar between the two treatment groups (P=0.17).
Conclusions
In this real-world retrospective study, there were no differences in PFS or OS between patients treated with afatinib or osimertinib in the first-line setting. These findings should be further investigated in larger prospective studies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacy, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
- Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center, Tampa, FL, USA.
- Department of Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
- Department of Oncologic Sciences, Morsani College of Medicine, University of South Florida, Tampa, FL, USA.
- Department of Pharmacy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Zitieren
APA
Gilardone, S., Thapa, R., Laborde, J., Shafique, M., Saltos, A., Creelan, B., Tanvetyanon, T., Chiappori, A., Simon, G., Haura, E. B., Gray, J. E., Chen, D. T., Melzer, D., & Pellini, B. (2023). Osimertinib vs. afatinib as first-line treatment for patients with metastatic non-small cell lung cancer with an EGFR exon 19 deletion or exon 21 L858R mutation. Journal of Thoracic Disease, 15(11), 6115-6125. https://doi.org/10.21037/jtd-23-686
Vancouver
Gilardone S, Thapa R, Laborde J, Shafique M, Saltos A, Creelan B, et al. Osimertinib vs. afatinib as first-line treatment for patients with metastatic non-small cell lung cancer with an EGFR exon 19 deletion or exon 21 L858R mutation. Journal of Thoracic Disease. 2023;15(11):6115-6125. doi:10.21037/jtd-23-686
BibTeX
@article{Gilardone2023,
author = {Gilardone, Sophia and Thapa, Ram and Laborde, José and Shafique, Michael and Saltos, Andreas and Creelan, Ben and Tanvetyanon, Tawee and Chiappori, Alberto and Simon, George and Haura, Eric B and Gray, Jhanelle E and Chen, Dung-Tsa and Melzer, Daniel and Pellini, Bruna},
title = {Osimertinib vs. afatinib as first-line treatment for patients with metastatic non-small cell lung cancer with an EGFR exon 19 deletion or exon 21 L858R mutation},
journal = {Journal of Thoracic Disease},
year = {2023},
volume = {15},
number = {11},
pages = {6115--6125},
doi = {10.21037/jtd-23-686}
}
EUVIMED